Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aerpio Pharmaceuticals is a biotechnology business based in the US. Aerpio Pharmaceuticals stocks (ARPO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.76 – an increase of 0.59% over the previous week. Aerpio Pharmaceuticals employs 12 staff and has a market cap (total outstanding stock value) of $104.9 million.
|Latest market close||$1.70|
|52-week range||$1.62 - $30.00|
|50-day moving average||$31.63|
|200-day moving average||$25.85|
|Wall St. target price||$22.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.41|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2022-05-13)||N/A|
|1 month (2022-04-20)||N/A|
|3 months (2022-02-20)||N/A|
|6 months (2021-11-20)||N/A|
|1 year (2021-05-24)||-2.30%|
|2 years (2020-05-22)||117.95%|
|3 years (2019-05-24)||58.14%|
|5 years (2017-05-20)||N/A|
|Gross profit TTM||$15 million|
|Return on assets TTM||-31.02%|
|Return on equity TTM||-47.61%|
|Market capitalisation||$104.9 million|
TTM: trailing 12 months
We're not expecting Aerpio Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Aerpio Pharmaceuticals's shares have ranged in value from as little as $1.62 up to $30. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerpio Pharmaceuticals's is 1.6466. This would suggest that Aerpio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.Read more…
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
Everything we know about the Wytec International IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.